CC
ARQT icon

Centiva Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Centiva Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,984
Closed -$67.8K – 1757
2023
Q4 		$67.8K Sell
20,984
-189,016
-90% -$514K ﹤0.01% 1623
2023
Q3 		$1.12M Buy
210,000
+120,000
+133% +$1.02M 0.02% 580
2023
Q2 		$858K Sell
90,000
-110,000
-55% -$1.22M 0.02% 625
2023
Q1 		$2.2M Buy
+200,000
New +$2.89M 0.05% 373
2022
Q4 		– Sell
-50,000
Closed -$956K – 1356
2022
Q3 		$956K Buy
+50,000
New +$1.13M 0.02% 643
2022
Q2 		– Sell
-25,729
Closed -$496K – 1675
2022
Q1 		$496K Buy
+25,729
New +$435K 0.01% 982

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Centiva Capital's ARQT Position: Q1 2024 in Review

Centiva Capital sold out of Arcutis Biotherapeutics (ARQT) in Q1 2024, closing a stake of 20,984 shares — an estimated $67.8K sold.

Centiva Capital first reported a position in ARQT in Q1 2022 and held it in 6 quarters. The position peaked at $2.2M in Q1 2023. 168 funds tracked by Wall St. Rank hold ARQT as of Q1 2024.

  • Centiva Capital reported no remaining Arcutis Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Centiva Capital sold 20,984 Arcutis Biotherapeutics shares in Q1 2024, an estimated $67.8K.
  • Centiva Capital first reported a position in Arcutis Biotherapeutics in Q1 2022 and held it in 6 quarters.
  • Centiva Capital's Arcutis Biotherapeutics position peaked at $2.2M in Q1 2023.
  • 168 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2024.

Based on Centiva Capital's 13F filing for Q1 2024, filed 15 May 2024.